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Abstract
The objective of the present study was to evaluate the aptitude of TRAIL gene expression for
inducing apoptosis in co-cultivated T-cells. This should allow preparing a strategy for the
development of a durable, allogenic skin substitute based on the induction of an immune-privileged
transplant. In order to counteract the significant potential of rejection in transplanted allogenic
keratinocytes, we created a murine keratinocyte cell line which expressed TRAIL through stable
gene transfer. The exogenic protein was localized on the cellular surface and was not found in
soluble condition as sTRAIL. Contact to TRAIL expressing cells in co-culture induced cell death in
sensitive Jurkat-cells, which was further intensified by lymphocyte activation. This cytotoxic effect
is due to the induction of apoptosis. We therefore assume that the de-novo expression of TRAIL
in keratinocytes can trigger apoptosis in activated lymphocytes and thus prevent the rejection of
keratinocytes in allogenic, immune-privileged transplants.
Introduction
Members of the TNF ligand family control and conduct
numerous immunological and inflammation-related
reactions. The Fas-FasL system and its associated mecha-
nism of activation-induced cell death play an important
role for the maintenance of hemostasis of the lymphoid
system and the induction of immune tolerance [1]. The
TNF-related apoptosis-inducing ligand (TRAIL) was iden-
tified as a homologue of the Fas-ligand (FasL) [2]. Yet, in
contrast to FasL, TRAIL expression has been demonstrated
in various tissues and organs [2-4], as the expression pat-
tern of TRAIL receptors allows a subtle observation of
apoptotic reactions. Until now, five different receptors for
TRAIL have been described and all belong to the TNF
receptor family. The receptors TRAIL-R1/DR4, TRAIL-R2/
DR5, TRAIL-R3/DcR1 and TRAIL-R4/DcR2 exhibit a con-
siderably homologous sequence of their extracellular
domain and bind TRAIL as the only known ligand. The
soluble receptor osteoprotegerin (OPG) belongs to a dif-
ferent sub-family and binds the ligand RANKL/OPGL as
well. Following ligand binding and activation of cytoplas-
matic death domains, TRAIL-R1 and TRAIL-R2 start series
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of signals for apoptosis [4,5], whereas the decoy receptors
do not transmit death signals. The ratio of expression of
DR4/DR5 and decoy receptors by a tumor cell will deter-
mine its sensibility for TRAIL-induced apoptosis [2,4]. An
important function of TRAIL is the regulation of the
immune response being involved in controlling the extent
of the activated lymhocyte reaction [6]. Interactions
between TRAIL and lymphocytes can create so-called
immune-privileged sites, e.g. the placenta [7].
The use of TRAIL for the induction of tolerance against all-
ogenic transplants should be considered in burn medi-
cine. The therapy of massive burn injuries is highly
complex and can result in grave personal and socio-eco-
nomic consequences. The therapeutic gold standard is the
early resection of necrotic tissue and subsequent wound
coverage with autologous skin transplants. Extensive burn
injuries are associated with a lack of sufficient donor areas
and the need for temporary allogenic or alloplastic cover-
age. However, allogenic transplants will ultimately be
rejected, once the patient regained immunological com-
petence. Allogenic keratinocytes exhibit a profound
intrinsic immunogenicity due to the antigen-presenting
properties of epidermal cells [8] which express MHC II
and a host of inflammatory cytokines. The resulting rejec-
tion of the transplant is predominantly T-cell mediated,
where even a small number of donor-specific T-cells can
lead to the complete destruction of the transplanted skin
[9]. Experimental data show that skin allografts are
rejected by either CD4+ or CD8+ T cells at any degree of
antigenic mismatch [10]. Consequently, the final wound
coverage has to consist of autologous split-thickness skin
grafts from repeatedly harvested donor sites. The progno-
sis of the patient can deteriorate due to rising numbers of
surgical interventions, immunological reactions against
the allotransplants, increasing danger of infection and
inadequate wound healing of the donor areas. The pro-
duction of autologous epidermal cells from full-thickness
skin biopsies is hampered by long intervals of cultivation
of up to three weeks. The long-term quality and stability
of these keratinocyte sheets are inferior to alternative
methods of coverage [11].
The development of a storable, cutaneous allo-transplant
with a reduced immunogenic reactivity could help to
solve most of these problems.
The aim of this study was to evaluate a concept for the
induction of tolerance through the genetic transfer of
TRAIL cDNA in keratinocytes to produce a localized lym-
phocytic apoptosis. We investigated whether the transfer
of the TRAIL gene in cultivated keratinocytes could be
cytotoxic for co-cultivated T-cells. Our results show that
the constituitive expression of TRAIL after direct contact
between effector and target cells will successfully trigger
apoptosis in T-cells and thereby limit the transplant rejec-
tion. The use of keratinocytes expressing TRAIL could cre-
ate an immune-privileged status for the successful transfer




The murine epithelial cell line JB6 (American Type Cul-
ture Collection, Manassas, VA) was cultured in MEM with
10% fetal calf serum (FCS), 2 mM Glutamine and 1%
non-essential amino acids (Biochrom, Berlin, Germany)
at 37°C and 5% CO2 in humidified atmosphere. The
human T lymphoblastoma Jurkat cell line was maintained
in RPMI supplemented with 10% FCS. For co-culture
experiments JB6 cells were plated at a densitiy of 2,5 105/
ml in six well tissue culture plates. Jurkat cells were either
used untreated or stimulated for two days with ConA (1
μg/ml). Cells were washed and grown co-cultured for 48
hours in RPMI with 10% FCS.
Reagents  Antibodies directed against the C-terminus of
TRAIL were obtained from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA) (clone: D-3) and BD Pharmingen (San
Diego, CA) (clone: B5.1). Antibodies directed against the
N-terminus of TRAIL were obtained from Chemicon
(Temecula, CA). Antibodies directed against Caspase 8
were obtained from Santa Cruz Biotechnology. Secondary
antibodies were purchased from Sigma (Taufkirchen, Ger-
many) and Molecular Probes (Leiden, The Netherlands),
respectively. Recombinant human TRAIL was obtained
from Calbiochem (Schwalbach, Germany).
Generation of TRAIL producing cell clones
Full length TRAIL cDNA was cloned from a human lym-
phoma cDNA library (Lym12, Invitrogen, CA) using -ATG
GCT ATG ATG GAG GTC- as 5' and -TTA GCC AAC TAA
AAA GGC- as 3' primer, according to the published
sequence (GeneBank accession number: U37518), and
cloned into the expression vector pcDNA5/FRT (Invitro-
gen). For generating transfected cell lines JB6 pFRT/lac
Zeo cells were transfected with the expression vector and
pUG44 with the non-liposomal transfection reagent
FuGene6 (Roche Molecular Biochemicals, Mannheim)
following the supplier's instructions. Recombinant cells
were selected with Hygromycin B (Calbiochem). β-galac-
tosidase expression was measured by a specific ELISA
obtained by Roche Molecular Biochemicals (Mannheim,
Germany) and performed according to instructions and
visualized by staining with 5-bromo-4-chloro-3-indolyl-
beta-D-galactopyranoside (X-Gal).
Immunofluorescent staining
Cells were fixed in 4% Paraformaldehyde for twenty min-
utes at room temperature. Intracellular staining wasAnnals of Surgical Innovation and Research 2009, 3:13 http://www.asir-journal.com/content/3/1/13
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achieved by treatment with 0.2% Triton-X-100. After
blocking in 2% FCS/PBS cells were incubated with pri-
mary antibodies followed by secondary antibodies cou-
pled to Alexa 488 or Alexa 546, respectively, at 37°C for 1
hour. Cells were covered with vector shield (Molecular
probes) and examined by immunofluorescence micros-
copy.
Western Blot Analysis
Cells were harvested by centrifugation at 300 g, the pellet
was resuspended in 100 μl RIPA buffer (10 mM Tris, pH8,
150 mM NaCl, 1% Nonidet P-40, 0.5% sodium desoxy-
cholate, 0.1% sodium dodecyl sulfate (SDS), 1 mM phe-
nylmethylsulfonyl fluoride, 4 μg/ml aprotinine, 1 mM
sodium orthovanadate), sonicated and spun at 16600 g
for 5 min to remove insoluble material. The protein con-
tent was determined by Bradford assay. Samples were
mixed with Laemmli buffer and subjected to SDS-polyacr-
ylamide gel electrophoresis followed by Western blotting
to nitrocellulose membrane using standard techniques.
Filters were blocked in 5% non-fat dried milk supple-
mented with 0.05% Tween 20. Immunodetection was
performed either for 1 hour at room temperature or at
4°C over night with the antibodies of interest. NBT/BCIP
(Roche) was used as a substrate to detect bound antibody.
Detection of cell death
FITC-Annexin V (Roche) staining was performed accord-
ing to the manufacturer's instructions. After staining the
cells were examined by immunofluorescence. Quantifica-
tion of apoptotic cells was done with Apo-One assay
(Promega) as recommended by the manufacturer. In
brief, Jurkat cells were harvested from the co-cultures after
48 hours. 10000 cells were seeded into 96 well plates in
RPMI medium. 100 μl substrate reagent was added and
incubated at 37°C for one hour. Fluorescence was meas-
ured at 485 nm with a fluorescence reader (Genios, Tecan,
Austria).
Proliferation assays
To quantify proliferation commercial kits (Cell titre blue,
Promega) were used. 10000 Jurkat cells were seeded into
96 well plates. Substrate was added according to the man-
ufacturer's instructions. Incubation was done at 37°C for
one hour. The plates were read out at 590 nm.
ELISA  To detect soluble TRAIL in cell culture medium
ELISA (Biosource) was performed. Supernatants were col-
lected from cells after 48 hours of cultivation. Adherent
cells were lysed. Protein concentrations were determined
using Bradford assay and normalised. Samples were
added to precoated 96 well plates and ELISA was carried
out as recommended by the manufacturer.
Statistics
Data were collected from at least three independent exper-
iments and are presented as the mean and SEM. The sig-
nificance was determined by student's T test.
Results
Generating a keratinocyte cell-line to express TRAIL
The present study investigated the capacity of overex-
pressed TRAIL to induce apoptosis in co-cultivated T-cells.
In order to achieve higher reproducibility and standardi-
zation of results, we used stably transfected cells. A host
cell line was established integrating a stable gene expres-
sion cassette with a lacZ-zeocin fusion gene. The hybrid
gene was transcribed under the constitutive CMV pro-
moter. However, the efficacy of the transcription may vary
depending on the genomic insertion point of the inte-
grated gene box. As a precaution, we used genetically iden-
tical cell clones to determine the rate of lacZ expression.
LacZ expression in the JB6 host cell line Figure 1
LacZ expression in the JB6 host cell line. The murine 
keratinocyte cell line JB6 was transfected with a FRT flanked 
lacZ-Zeocin expression cassette. Clone JB6-pFRTLACZeo-7 
was chosen for single genomic integration of the cassette and 
high β-galactosidase expression. a ELISA measurement of the 
rate of expression of β-galactosidase in chosen cell clones. 
Clone JB6-pFRTLACZeo-7 is indicated as a grey bar. b For-
maldehyde fixated JB6-pFRTLACZeo-7 cells dyed with X-Gal.Annals of Surgical Innovation and Research 2009, 3:13 http://www.asir-journal.com/content/3/1/13
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Fig 1b depicts a murine keratinocyte derived from clone
JB6-pFRTLACZeo-7, which was incubated with the galac-
tose equivalent X-Gal following fixation with formalde-
hyde. The rate of expression of β-galactosidase was
ascertained with ELISA measurements (fig 1a). The clones
exhibiting the highest expression of β-galactosidase were
examined for the genomic integration of the gene box
with Southern Blot technique (fig 1c). Clone 7 showed
not the highest rates of expression. Yet, it was selected as
the host cell line because the integration of a single gene
box promised higher uniformity for the further course of
the study.
The lacZ-zeocin cassette flanked by FRT sites can be
exchanged for another FRT flanked gene box, if a Flp
recombinase derived from S. cerevisae is co-expressed. The
insertion of the entire cDNA for TRAIl was intended. The
complete open reading frame for TRAIL was amplified
from a human B-cell lymphoma cDNA library with spe-
cific primers developed from the published sequence
(Accession number: U37518). It was then cloned into the
vector pcDNA5/FRT and checked by sequencing. The
resulting expression vector was used to examine whether
the recombinant expression of TRAIL in keratinocytes
could trigger apoptosis in co-cultivated T-cells.
Transfected cells express TRAIL as a functional membrane 
protein
TRAIL has been identified as a homologue member of the
TNF family and represents a type II transmembrane pro-
tein [2]. It can exist in a soluble condition, which can
either be secreted in micro-vesicles [12] or split off the cel-
lular surface [13]. In order to demonstrate that JB6 cells
can express TRAIL constitutively as a functional integral
membrane protein, they were transfected with an expres-
sion box of human TRAIL cDNA. The cell clone
JB6pcDNA5/FRT TRAIL resulted from transfection of the
murine host cell line JB6pFRTlacZeo clone 7 with the con-
structed TRAIL vector and the cDNA for a Flp recombinase
(pUG44, Invitrogen) followed by a hygromycin selection
for recombinants. This particular cell clone was negative
for the expression of lacZ and zeocin, but postive for the
expression of TRAIL. Using Western Blot technique with
TRAIL specific mabs, a 33 kDa band was detected in the
total cell lysate of JB6pcDNA5/FRT TRAIL cells (fig 2a).
This finding is equivalent to the size of membrane-bound
TRAIL. Cells, which had a bacterial CAT gene inserted,
instead of the TRAIL gene, did not exhibit a corresponding
band. Thus, an expression of endogenic TRAIL was not
demonstrated in these cells.
Immunofluorescence microscopy was conducted to show
the localization of the gene products expressed (fig 2b).
JB6pcDNA5/FRT TRAIL cells exhibited a strong mem-
brane-bound fluorescence which, in contrast, was absent
in the control groups of non-transfected or CAT trans-
fected cells. The right orientation of the exogenous protein
was confirmed by two different antibodies binding to the
N-terminus and the C-terminus only. It showed the cyto-
plasmic N-terminus could only be detected when the cells
were permeabilised with Triton-X-100 (fig 2b).
Jurkat cell co-cultivated with keratinocytes expressing 
TRAIL undergo increased cell death
TRAIL is cytotoxic for Jurkat cells through binding on the
TRAIL receptor TRAIL R2/DR5. In order to demonstrate
the functional activity of TRAIL expressed by the cell clone
JB6, Jurkat cells sensitive to TRAIL [14] were placed in co-
culture with the cell clone. The survival rate of the Jurkat
cells was examined using an MTT proliferation assay.
Apoptosis was measured using a fluorescent caspase sub-
strat assay Apo-One (Promega). The percentage of dead
TRAIL expression of cell line JB6-pcDNA5/FRT TRAIL Figure 2
TRAIL expression of cell line JB6-pcDNA5/FRT 
TRAIL. The lacZeo expression cassette was exchanged for 
the full-length cDNA of TRAIL by FRT recombination. The 
resulting cell clone was examined for TRAIL expression. a 
Western Blot of the cellular lysates of JB6pcDNA5/FRT 
TRAIL and JB6pcDNA5/FRT CAT. Immunostaining was per-
formed by treatment with anti-TRAIL followed by incuba-
tion with alkaline phosphatase conjugated secondary 
antibody and colour development of NBT/BCIP. b Indirect 
immunofluorescence of JB6pcDNA5/FRT TRAIL. Cells 
were fixated and incubated with anti-TRAIL either directed 
against the C terminus or directed against the N terminus. 
The intracellular domain is detected only if the cells are per-
meable.Annals of Surgical Innovation and Research 2009, 3:13 http://www.asir-journal.com/content/3/1/13
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Jurkat cells was calculated from three independent exper-
iments.
After an incubation period of 48 hrs, the Jurkat cells which
coexisted with the keratinocytes expressing TRAIL showed
an increased mortality rate when compared with the con-
trol group (Fig. 3). Culturing of the supernatant, in con-
trast, showed no cytotoxic effect on the Jurkat cells, which
was in accordance with the results of the ELISA. Co-cultur-
ing of Jurkat cells with the cell clone JB6pcDNA5/FRT
CAT, with the TRAIL gene replaced by the bacterial CAT
gene, did not cause increased cytotoxicity either. In order
to prevent a bias through contamination with JB6 cells, we
conducted control experiments without Jurkat cells (data
not shown). This control series showed no increased lev-
els of cell death. In addition, we determined the amount
of cell death found in the JB6 cells in co-culture, which
were found to be accordingly low. The results of the co-
culture experiments are not due to detached apoptotic JB6
cells. The cell clone produced for our study proved cyto-
toxic for cells sensitive to TRAIL, which is localized on the
cell surface.
Next, the Jurkat cells were stimulated with concanavaline
A and placed in the co-cultures. Stimulation with ConA
induces an increase of the endogenous expression of
TRAIL in T cells [13] and also enhances the autocrine and
paracrine sensitivity for apoptosis induced by TRAIL. For
this purpose, the cells had been cultured in 1 μg/ml ConA
enriched media for 2 days. The cells were then thoroughly
washed and added to subconfluent JB6pcDNA5/FRT
TRAIL or JB6pcDNA5/FRT CAT, respectively. We found an
increase of the paracrine sensitivity for the membrane-
bound TRAIL in epithelial cells lines.
Cell contact of TRAIL transfected keratinocytes and T cells 
leads to caspase activation and apoptotic cell death
Cell death induced by TRAIL shares numerous similar
characteristics with other apoptosis promoting factors.
Examples are the activation of the caspase cascade, the
binding of Annexin V secondary to the shifting of cellular
phosphatidylserine and the fragmentation of DNA
[2,4,15]. Therefore, we wanted to investigate whether the
increased mortality rate of cells in co-culture with
JB6pcDNA5/FRT TRAIL was due to a triggered pro-
grammed cell death. Phase contrast microscopy of co-cul-
tured Jurkat cells demonstrated apoptotic bodies after 48
hrs (fig 4a). Fluorescence microscopy of co-cultured Jurkat
T cells using FITC-Annexin V/propidiumiodide double
staining showed that many Jurkat cells in co-culture with
JB6pcDNA5/FRT TRAIL were positive for FITC-Annexin V
after 48 hrs of incubation (fig 4b). Contamination of the
JB6 cells was excluded through measurement of cell size.
In the control group JB6pcDNA5/FRT CAT was placed in
co-culture with Jurkat cells. These control co-cultures
exhibited only very few apoptotic or necrotic cells (fig 4c,
d). Protein analysis of Jurkat cells kept in co-culture with
JB6pcDNA5/FRT TRAIL for 48 hrs showed the activation
of caspase 8 (fig 4e, lane 4). The same could be observed
for cells previously stimulated with concanavaline A (fig
4e, lane 5). Western blotting of cellular lysates from
untreated cells and cells kept in co-culture with
JB6pcDNA5/FRT CAT showed no activated caspase 8 (fig
4e, lanes 1-3). It was thus demonstrated that the contact
with JB6pcDNA5/FRT TRAIL will trigger the caspase
dependent programmed cell death in Jurkat cells.
Activation of apoptosis depends on the direct contact to 
TRAIL expressing keratinocytes
In order to determine the amount of membrane-bound
TRAIL cleaved by proteases, we performed a TRAIL specific
ELISA of the supernatant. Cell culture media of
JB6pcDNA5/FRT TRAIL was taken after 48 hrs of incuba-
tion and the cells were lysed in 500 μl lysis buffer after
removing adherent cells. The protein contents were deter-
mined by Bradford assay. TRAIL was quantified in both
fractions by ELISA. The result showed the presence of
TRAIL in the cellular extract but not in the supernatant,
indicating no detectable cleavage of TRAIL (fig 5a).
Percentage of dead Jurkat cells after 48 hrs in co-culture with  JB6pcDNA5/FRT TRAIL and CAT, respectively Figure 3
Percentage of dead Jurkat cells after 48 hrs in co-cul-
ture with JB6pcDNA5/FRT TRAIL and CAT, respec-
tively. Cells were either prestimulated with concanavaline A 
or left untreated. Cell viabiliy was measured by MTT assay 
while apoptosis was determined by the caspase substrat 
reaction Apo-One and the percentage of dead Jurkat cells 
was calculated. All experiments were carried out in tripli-
cates at least three independent times and presented as 
means with standard deviation. (p < 0,05 for the difference 
between cells expressing CAT and TRAIL, respectively.)Annals of Surgical Innovation and Research 2009, 3:13 http://www.asir-journal.com/content/3/1/13
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Further experiments were designed to determine the influ-
ence of direct cell contact of JB6pcDNA5/FRT TRAIL on
Jurkat cells compared to the supernatant. The cell viability
of Jurkat cells was measured by the conversion of resaz-
urin to the fluorescent resurufin (fig 5b). This conversion
depends directly on the viability of the cells. Jurkat cells
obtained after 48 hrs from a co-culture with JB6pcDNA5/
FRT TRAIL showed a decreased viability compared to the
untreated control cells. Viability of cells maintained in the
supernatant of JB6pcDNA5/FRT TRAIL cells was compara-
ble to the controls.
TRAIL expressing keratinocytes induce apoptosis in native 
T cells
In order to determine the effect of the co-culture on native
T cells, CD4+ and CD8+ cells were isolated from human
PBMCs using paramagnetic antibodies. After a 48 hr
period of co-culturing, the re-isolated cell populations
stained positive with FITC-Annexin V in contrast to cells
co-cultured with JB6pcDNA5/FRT CAT (fig 6b, d). Light
microscopy revealed characteristic signs of programmed
cell death, e.g. membrane blebbing and nuclear conden-
sation (fig 6a, c).
Discussion
The transplantation of allogenic skin as a live saving ther-
apy after massive burn injuries is an important issue for
the application of immuno-modulating strategies. The
The effect of TRAIL expression in JB6-pcDNA5/FRT TRAIL  cells on co-cultured Jurkat cells Figure 4
The effect of TRAIL expression in JB6-pcDNA5/FRT 
TRAIL cells on co-cultured Jurkat cells. A Phase-con-
trast-imaging of apoptotic Jurkat cell after 48 hours of co-cul-
ture with JB6-pcDNA5/FRT TRAIL. b Annexin V/
Propidiumiodide dyed Jurkat cells after 48 hours of co-cul-
ture with JB6-pcDNA5/FRT TRAIL. Membrane fluorescence 
is characteristic for apoptosis. c Phase-contrast-imaging of a 
Jurkat cell after 48 hours of co-culture with JB6-pcDNA5/
FRT CAT. d Annexin V/Propidiumiodide dyed Jurkat cell 
after 48 hours of co-culture with JB6-pcDNA5/FRT CAT. No 
membrane fluorescence could be detected. e Western blot 
stained with anti-Caspase 8 followed by alkaline phosphatase-
conjugated secondary antibody and NBT/BCIP colour devel-
opment on the blot. Lane 1: untreated Jurkat cells, Lane 2: 
Jurkat cells kept in co-culture with JB6pcDNA5/FRT CAT, 
Lane 3: Jurkat cells kept in co-culture with JB6pcDNA5/FRT 
CAT prestimulated with concanavaline A, Lane 4: Jurkat cells 
kept in co-culture with JB6pcDNA5/FRT TRAIL, Lane 5: Jur-
kat cells kept in co-culture with JB6pcDNA5/FRT TRAIL 
prestimulated with concanavaline A.
Influence of the exogenous expressed TRAIL depends on the  direct cell contact Figure 5
Influence of the exogenous expressed TRAIL 
depends on the direct cell contact. a ELISA quantifica-
tion of TRAIL. The supernatants of JB6pcDNA5/FRT TRAIL 
and JB6pcDNA5/FRT CAT cells were collected after 48 hrs 
of cultivation. The remaining cells were lysed. Protein con-
tents were determined and both fractions were subjected to 
ELISA specific for TRAIL. b Caspase activity in Jurkat cells 
kept in co-culture with JB6pcDNA5/FRT TRAIL and 
JB6pcDNA5/FRT CAT or the harvested cell culture superna-
tant were determined. Data are reported in relative fluores-
cence light units (RFLU) and presented as mean with 
standard deviation of three independent experiments. p < 
0,05 was regarded as statistically significant.Annals of Surgical Innovation and Research 2009, 3:13 http://www.asir-journal.com/content/3/1/13
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utilization of apoptosis-inducing properties of some
members of the TNF ligand family for the development of
immune-privileged transplants is a fascinating, yet highly
controversial means of allogenic transplantation. In a
mixed lymphocyte-endothelial cell culture model, Cap-
pellesso et al. showed that FasL transfected endothelial
cells were effective in inducing apoptosis in Jurkat T cells.
The authors conclude that expression of FasL in endothe-
lial cells could be interesting to convey a death signal and
induce hyporesponsiveness of allo reactive T cells for
organ transplantation [16]. The precise role of the FasL//
Fas system for the so-called tumor counter attack has not
been clarified yet [17-19]. Various data from in-vitro and
in-vivo studies suggest an association between the expres-
sion of FasL, which is present in numerous tumours [20-
23], and a significant localized reduction of tumor-infil-
trating lymphocytes (TILs)[24] secondary to apoptosis of
sensitive T-cells [23,25]. FasL acts in an analogous func-
tion to establish an immune-privileged status for special
tissues, thereby protecting delicate organs like the eye
against potential damage from immunological reactions
[26]. Similar findings were noticed for TRAIL, which
shares numerous characteristics with FasL. The functional
expression of TRAIL was demonstrated in human colon
adenocarcinoma cell lines [27], possibly representing a
biochemical mechanism of tumor escape in analogy to
the FasL expression. FasL and TRAIL conjointly contribute
to the immune-privileged status of the placenta [7]. In
order to evaluate the potential capability of TRAIL gene
expression to induce tolerance through the initiation of
apoptosis in a localized T cell population, we produced a
keratinocyte clone expressing TRAIL which would trigger
apoptosis in co-cultured Jurkat cells.
We showed how the stable transfection of a complete
cDNA of TRAIL with a strong, constituitive promoter will
lead to a lasting expression of membrane-bound, func-
tional TRAIL on the cell surface of the transfected kerati-
nocyte cell line. Jurkat cells are sensitive for the
cytotoxicity mediated by TRAIL because of the expression
of death-inducing receptors like TRAIL-R2/DR5 [2,4].
Inoue et al. showed how apoptosis in Jurkat cells can be
triggered by tumor cells using a TRAIL dependant signal
pathway [27]. In analogy to FasL, TRAIL can be expressed
in many different tumor cells, ranging from breast- and
braintumors to myeloid, lymphoid and colon carcinoma
cells. Although the significance of FasL and TRAIL for the
establishment of tumors has not been clarified in vivo, the
induction of apoptosis represents an effective mechanism
for the selective limitation of TILs, which can possibly be
applied in transplants. The findings of our study show a
pronounced cytotoxicity of complete TRAIL on TRAIL sen-
sitive Jurkat cells and freshly isolated CD4+ and CD8+
cells. The cells will die due to a programmed cell death
mediated by caspase. The cytotxic effect on Jurkat cells can
be amplified by previous activation and incubation with
ConA in a so-called activation induced cell death. The cell
clone JB6pcDNA5/FRT TRAIL can induce apoptosis in T
cells on direct contact and can thus effect a localized
reduction of the total number of T cells.
There was no detectable secretion of sTRAIL in the cell cul-
ture media with the culturing conditions chosen in this
study. The exposure of TRAIL sensitive Jurkat cells to the
cell culture supernatant did not produce a cytotoxic effect,
however, direct cell contact in the co-culture led to apop-
tosis in the target cells. An increase of the content of
sTRAIL in humans can possibly produce hepatotoxicity
and must be carefully considered before the application of
specific gene therapy [28,29]. Although TRAIL represents
a type II transmembrane-protein, it can also exist in a sol-
uble condition following processing and it will exhibit
tumoricidal activity [15,30,31]. sTRAIL can mediate apop-
totic signals into cells through interaction with the recep-
tors TRAIL-R1/DR4 and TRAIL-R2/DR5. sTRAIL, however,
is not as effective as membrane-bound TRAIL [32,33],
which is probably due to conformational differences
[34,35]. A gene-therapeutic strategy with foreign gene
expression in the target cells should be considered as an
Co-culturing of JB6pcDNA5/FRT TRAIL with native T cells Figure 6
Co-culturing of JB6pcDNA5/FRT TRAIL with native 
T cells. a Phase-contrast-imaging of a apoptotic CD4+ cell 
after 48 hours of co-culture with JB6-pcDNA5/FRT TRAIL. b 
Annexin V/Propidiumiodide dyed CD4+ cell after 48 hours of 
co-culture with JB6-pcDNA5/FRT TRAIL. Membrane fluores-
cence is characteristic for apoptosis. c Phase-contrast-imag-
ing of a CD8+ cell after 48 hours of co-culture with JB6-
pcDNA5/FRT TRAIL. d Annexin V/Propidiumiodide dyed 
CD8+ cell after 48 hours of co-culture with JB6-pcDNA5/
FRT TRAIL.Annals of Surgical Innovation and Research 2009, 3:13 http://www.asir-journal.com/content/3/1/13
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alternative option in cancer therapy as well as for the
induction of immunological tolerance in allogenic trans-
plants.
Further studies using animal models are required to inves-
tigate if TRAIL expression in transplanted keratinocytes
can induce immunological tolerance. The long-term
effects of TRAIL expression on the inflammatory phase of
wound healing as well as the interaction with other der-
mal cells are currently under investigation.
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